Time Trade-off Utility Values in Noninfectious Uveitis.
Administration, Oral
Adult
Antidepressive Agents
/ administration & dosage
Cross-Sectional Studies
Female
Glucocorticoids
/ administration & dosage
Health Status
Health Surveys
Humans
Male
Middle Aged
Quality of Life
/ psychology
Sickness Impact Profile
Surveys and Questionnaires
Tertiary Care Centers
Uveitis
/ physiopathology
Visual Acuity
/ physiology
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
12
03
2019
revised:
04
06
2019
accepted:
05
06
2019
pubmed:
16
6
2019
medline:
28
3
2020
entrez:
16
6
2019
Statut:
ppublish
Résumé
To investigate time trade-off (TTO) utility values in patients with noninfectious uveitis and determine whether patient demographics and clinical characteristics are associated with utility scores. Time trade-off utility analysis. Setting: A tertiary care uveitis center in San Francisco, California, USA. One hundred and four consecutive adults with noninfectious uveitis, enrolled between November 2016 and February 2017. TTO utility values, as collected by an interviewer-guided survey. Information regarding general health, ocular symptoms, and religion was also collected and medical record review was conducted to record anatomic location of uveitis, disease activity, visual acuity, and treatments. Multivariable regression analysis with backward selection was used to identify variables associated with TTO values. Median TTO score was 0.975 (interquartile range [IQR]: 0.8-1.0), corresponding to trading a median 1.28 years of remaining life for healthy eyes (IQR: 0-6.29). Regression analysis revealed that worse eye visual acuity, >6 months of oral corticosteroid use, and current antidepressant use were associated with lower TTO scores (P = .008, P = .006, P = .008, respectively), controlling for age and sex. In particular, patients who had been taking oral corticosteroids for more than 6 months, regardless of dose, were 10.5 times more likely to trade 20% or more years of remaining life (TTO ≤0.8) than patients not taking oral corticosteroids (95% confidence interval: 2.3, 48.1; P = .002). Patients with noninfectious uveitis had measurable, though modest, reductions in quality of life, as assessed by TTO, and these decreases were significantly associated with visual acuity in the worse eye and long-term oral corticosteroid use.
Identifiants
pubmed: 31201795
pii: S0002-9394(19)30272-7
doi: 10.1016/j.ajo.2019.06.005
pmc: PMC6888854
mid: NIHMS1537645
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Glucocorticoids
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-55Subventions
Organisme : NEI NIH HHS
ID : U10 EY021125
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Ocul Immunol Inflamm. 2017 Aug;25(4):486-491
pubmed: 27002552
BMC Ophthalmol. 2012 Aug 21;12:43
pubmed: 22909264
Psychol Bull. 2008 Mar;134(2):163-206
pubmed: 18298268
Eur J Health Econ. 2013 Jul;14 Suppl 1:S53-64
pubmed: 23900665
Ophthalmology. 2013 Sep;120(9):1736-44
pubmed: 23664469
Ocul Immunol Inflamm. 2019;27(5):731-742
pubmed: 29969331
Br J Ophthalmol. 2011 May;95(5):699-704
pubmed: 20971789
Pharmacoeconomics. 2016 Oct;34(10):993-1004
pubmed: 27084198
Arch Ophthalmol. 2001 Jun;119(6):841-9
pubmed: 11405835
PLoS One. 2016 Jan 25;11(1):e0146956
pubmed: 26808922
Ophthalmology. 2016 Mar;123(3):655-62
pubmed: 26712559
Ocul Immunol Inflamm. 2010 Aug;18(4):297-304
pubmed: 20482406
Ophthalmic Epidemiol. 2015 Feb;22(1):20-7
pubmed: 24669801
J Health Econ. 1986 Mar;5(1):1-30
pubmed: 10311607
Ophthalmic Epidemiol. 2011 Oct;18(5):233-43
pubmed: 21961513
J Chronic Dis. 1987;40(6):593-603
pubmed: 3298297
Can J Ophthalmol. 2000 Aug;35(5):267-72
pubmed: 10959467
Trans Am Ophthalmol Soc. 2001;99:301-17
pubmed: 11797316
Qual Life Res. 2015 Nov;24(11):2565-75
pubmed: 26038219
Lancet. 1997 Oct 4;350(9083):979-82
pubmed: 9329512
Med Decis Making. 2015 Jan;35(1):6-11
pubmed: 24759686
Qual Life Res. 2016 Dec;25(12):2997-3008
pubmed: 27444779
Qual Life Res. 2014 Mar;23(2):377-84
pubmed: 23943291
Br J Ophthalmol. 2009 Jul;93(7):871-4
pubmed: 19208679
Health Econ. 1996 Mar-Apr;5(2):141-54
pubmed: 8733106
Am J Ophthalmol. 1999 Sep;128(3):324-30
pubmed: 10511027
Soc Sci Med. 2002 Mar;54(6):919-29
pubmed: 11996025
Ophthalmic Epidemiol. 2004 Feb;11(1):43-51
pubmed: 14977496
Arch Ophthalmol. 2002 Apr;120(4):481-4
pubmed: 11934322
Respir Med. 2015 Apr;109(4):526-31
pubmed: 25698652
Gerontologist. 1999 Jun;39(3):271-8
pubmed: 10396885
Trans Am Ophthalmol Soc. 2001;99:199-203; discussion 203-4
pubmed: 11797307
Can J Ophthalmol. 2001 Jun;36(4):202-9
pubmed: 11428529
Acta Ophthalmol. 2016 Aug;94(5):e331-9
pubmed: 26932535
JAMA Ophthalmol. 2013 Feb;131(2):219-25
pubmed: 23411886
JAMA. 2016 May 24-31;315(20):2230-2
pubmed: 27218634
Clin Ophthalmol. 2014 Mar 12;8:529-35
pubmed: 24648717
Br J Ophthalmol. 1996 Apr;80(4):332-6
pubmed: 8703885
Br J Ophthalmol. 1996 Sep;80(9):844-8
pubmed: 8962842
Osteoporos Int. 2004 Apr;15(4):323-8
pubmed: 14762652
Int Ophthalmol. 1990 Oct;14(5-6):303-8
pubmed: 2249907
Optom Vis Sci. 2013 Aug;90(8):855-60
pubmed: 23811607
Jpn J Ophthalmol. 2011 Jan;55(1):35-8
pubmed: 21331690
Health Econ. 2011 Dec;20(12):1407-16
pubmed: 20967923
Qual Life Res. 2013 Aug;22(6):1507-14
pubmed: 23054488
Arthritis Rheum. 2006 Jun 15;55(3):420-6
pubmed: 16739208
Ocul Immunol Inflamm. 2018;26(7):1078-1093
pubmed: 28548554
Value Health. 2012 May;15(3):475-84
pubmed: 22583458
Ocul Immunol Inflamm. 2018;26(5):717-725
pubmed: 28323495
Med Decis Making. 2001 Mar-Apr;21(2):122-32
pubmed: 11310945
Invest Ophthalmol Vis Sci. 2014 Mar 06;55(3):1361-9
pubmed: 24519425
Am J Ophthalmol. 2012 Feb;153(2):370-378.e2
pubmed: 21924399
Arch Ophthalmol. 2000 Jan;118(1):47-51
pubmed: 10636413
Am J Ophthalmol. 2011 Jul;152(1):60-65.e1
pubmed: 21570045